Comment www.thelancet.com www.thelancet.com Vol 377 February 12, 2011 Stemming the global tsunami of cardiovascular disease.

Slides:

Advertisements

Similar presentations

Effect of a dietary Portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia Erin Woodard.

Advertisements

Developing a Chronic Disease Model of Care for Coronary Artery Disease and Depression in Rural Settings Dr Steve Bunker Prof James Dunbar Dr Prasuna Reddy.

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

INFLAMACION Y ENFERMEDAD CARDIOVASCULAR.

Zacho J, et al. N Engl J Med 2008;359: Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Relation between Cardiovascular Disease Risk Markers and Brain Infarcts Detected by Magnetic Resonance Imaging in an Elderly Population Ruta Nylander,

Genetic variation at chromosome 1p13

LDL cholesterol in CKD—to treat or not to treat?

2013 ACC/AHA cholesterol treatment guidelines

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Melody Sherwood, Peter A McCullough The Lancet Global Health

Kerry-Anne Rye, Kwok Leung Ong The Lancet Diabetes & Endocrinology

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

TNT: Baseline and final LDL cholesterol levels

Figure 7 Mendelian randomization of overlapping exposures

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

The epidemiology of the atopic child

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Reducing the Burden of Stage B Heart Failure and the Global Pandemic of Cardiovascular Disease: Time to Go to War with the “Barefoot” Troops! Ragavendra.

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Jari A. Laukkanen, MD, PhD, Tanjaniina Laukkanen, MSc, Setor K

Volume 375, Issue 9709, Pages (January 2010)

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Effects of Self-care Health Behaviors on Quality of Life Mediated by Cardiovascular Risk Factors Among Individuals with Coronary Artery Disease: A Structural.

Peripheral Arterial Disease: Diagnosis and Management

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Nat. Rev. Cardiol. doi: /nrcardio

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Cardiorespiratory Fitness: An Independent and Additive Marker of Risk Stratification and Health Outcomes Barry A. Franklin, PhD, Peter A. McCullough,

Reducing the Burden of Stage B Heart Failure and the Global Pandemic of Cardiovascular Disease: Time to Go to War with the “Barefoot” Troops! Ragavendra.

Cardiovascular Disease and CKD: Core Curriculum 2010

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

James H. O'Keefe, M.D., Carl J. Lavie, M.D., Ben D. McCallister, M.D.

OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.

Primary and Secondary Prevention of Cardiovascular Disease

Melody Sherwood, Peter A McCullough The Lancet Global Health

Arnaud Chiolero The Lancet Public Health

Volume 379, Issue 9822, Pages (March 2012)

Kerry-Anne Rye, Kwok Leung Ong The Lancet Diabetes & Endocrinology

2013 ACC/AHA cholesterol treatment guidelines

Contemporary Evidence-Based Guidelines

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention Abdallah Al-Salameh, MD, Philippe Chanson,

LDL cholesterol in CKD—to treat or not to treat?

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Volume 73, Issue 12, Pages (June 2008)

A.V. Khera et al. N Engl J Med 2011;364:127-35

Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Characteristics of the Subjects*

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

Guidelines should bother us, not comfort us

Calcium on trial: Beyond a reasonable doubt?

PROSPER: trial design

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Cardiovascular risk in chronic kidney disease

Change in markers of glycometabolism and cardiovascular risk profile.

The Obesity Paradox: Perception vs Knowledge

A large international single-center case-series of coronary artery fistulas in children: When high clinical research standards adopted globally create.

Traditional cardiovascular risk factors can cause cardiac disease in patients with IIM. Systemic and local inflammation may either have a direct effect.

Presentation transcript:

Comment Vol 377 February 12, 2011 Stemming the global tsunami of cardiovascular disease

An epidemic of risk factors for cardiovascular disease The Lancet, Volume 377, Issue 9765, Page 527, 12 February 2011

INFLAMACION Y ENFERMEDAD CARDIOVASCULAR

CRP: star trekking the galaxy of risk markers

Editorial C reactive protein and the risk of cardiovascular disease

Are clearly linked but a causal association is unlikely Editorial

Figure 2

MICROBIOMA HUMANO Y ENFERMEDAD CARDIOVASCULAR

LDL Y ENFERMEDAD CARDIOVASCULAR: MÁS ALLÁ DE LAS ESTATINAS

HDL Y ENFERMEDAD CARDIOVASCULAR

HDL and Cardiovascular-Disease Risk Time for a New Approach? N Engl J Med 2011; 364: January 13, 2011 Editorial Jay Heinecke, M.D.

Clinical Implications of Basic Research Sorting Out Cholesterol and Coronary Artery Disease Patrick Linsel-Nitschke, M.D., Nilesh J. Samani, M.D., M.B., Ch.B., and Heribert Schunkert, M.D. N Engl J Med 2010; 363:

Sortilin 1 and the Risk of Coronary Disease. Linsel-Nitschke P et al. N Engl J Med 2010;363:

EPIGENÉTICA Y ENFERMEDAD CARDIOVASCULAR

INSULINORESISTENCIA Y ENFERMEDAD CARDIOVASCULAR

A Comparison of PPARγ Activity in Lean and Obese Persons. Kahn BB, McGraw TE. N Engl J Med 2010;363:

NUTRICIÓN Y ENFERMEDAD CARDIOVASCULAR

Volume 362: June 3, 2010Number 22

REPROGRAMACIÓN CELULAR Y ENFERMEDAD CARDIOVASCULAR

Clinical Implications of Basic Research Reprogramming Fibroblasts into Cardiomyocytes Charles E. Murry, M.D., Ph.D., and William T. Pu, M.D. N Engl J Med 2011; 364:177-17

The Path from Fibroblast to Cardiomyocyte. Murry CE, Pu WT. N Engl J Med 2011;364:

LA POBREZA Y ENFERMEDAD CARDIOVASCULAR